These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6630 related articles for article (PubMed ID: 12794025)

  • 1. Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients.
    Rousseau DL; Ross MI; Johnson MM; Prieto VG; Lee JE; Mansfield PF; Gershenwald JE
    Ann Surg Oncol; 2003 Jun; 10(5):569-74. PubMed ID: 12794025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Joint Committee on Cancer clinical stage as a selection criterion for sentinel lymph node biopsy in thin melanoma.
    Vaquerano J; Kraybill WG; Driscoll DL; Cheney R; Kane JM
    Ann Surg Oncol; 2006 Feb; 13(2):198-204. PubMed ID: 16418885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-institution experience in the management of patients with clinical stage I and II cutaneous melanoma: results of sentinel lymph node biopsy in 240 cases.
    Rex J; Paradelo C; Mangas C; Hilari JM; Fernández-Figueras MT; Fraile M; Alastrué A; Ferrándiz C
    Dermatol Surg; 2005 Nov; 31(11 Pt 1):1385-93. PubMed ID: 16416605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role for lymphatic mapping and sentinel lymph node biopsy in patients with thick (> or = 4 mm) primary melanoma.
    Gershenwald JE; Mansfield PF; Lee JE; Ross MI
    Ann Surg Oncol; 2000 Mar; 7(2):160-5. PubMed ID: 10761797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
    Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
    Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A nomogram that predicts the presence of sentinel node metastasis in melanoma with better discrimination than the American Joint Committee on Cancer staging system.
    Wong SL; Kattan MW; McMasters KM; Coit DG
    Ann Surg Oncol; 2005 Apr; 12(4):282-8. PubMed ID: 15827679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sentinel Lymph Node Genes to Predict Prognosis in Node-Positive Melanoma Patients.
    Hao H; Xiao D; Pan J; Qu J; Egger M; Waigel S; Sanders MA; Zacharias W; Rai SN; McMasters KM
    Ann Surg Oncol; 2017 Jan; 24(1):108-116. PubMed ID: 27663566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sentinel lymph node biopsy for cutaneous melanoma: the Stanford experience, 1997-2004.
    Berk DR; Johnson DL; Uzieblo A; Kiernan M; Swetter SM
    Arch Dermatol; 2005 Aug; 141(8):1016-22. PubMed ID: 16103331
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel and accurate computer model of melanoma prognosis for patients staged by sentinel lymph node biopsy: comparison with the American Joint Committee on Cancer model.
    Callender GG; Gershenwald JE; Egger ME; Scoggins CR; Martin RC; Schacherer CW; Edwards MJ; Urist MM; Ross MI; Stromberg AJ; McMasters KM
    J Am Coll Surg; 2012 Apr; 214(4):608-17; discussion 617-9. PubMed ID: 22342785
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma.
    Kruper LL; Spitz FR; Czerniecki BJ; Fraker DL; Blackwood-Chirchir A; Ming ME; Elder DE; Elenitsas R; Guerry D; Gimotty PA
    Cancer; 2006 Nov; 107(10):2436-45. PubMed ID: 17058288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The new staging system for cutaneous melanoma in the era of lymphatic mapping.
    Rousseau DL; Gershenwald JE
    Semin Oncol; 2004 Jun; 31(3):415-25. PubMed ID: 15190500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of the AJCC 7th edition change in T1 melanoma substaging on national utilization and outcomes of sentinel lymph node biopsy for thin melanoma.
    Hieken TJ; Grotz TE; Comfere NI; Inselman JW; Habermann EB
    Melanoma Res; 2015 Apr; 25(2):157-63. PubMed ID: 25647736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is mitotic rate still useful in the management of patients with thin melanoma?
    Tejera-Vaquerizo A; Pérez-Cabello G; Marínez-Leborans L; Gallego E; Oliver-Martínez V; Martín-Cuevas P; Arias-Santiago S; Aneiros-Fernández J; Herrera-Acosta E; Traves V; Herrera-Ceballos E; Nagore E
    J Eur Acad Dermatol Venereol; 2017 Dec; 31(12):2025-2029. PubMed ID: 28750139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Staging of regional lymph nodes in melanoma: a case for including nonsentinel lymph node positivity in the American Joint Committee on Cancer staging system.
    Leung AM; Morton DL; Ozao-Choy J; Hari DM; Shin-Sim M; Difronzo AL; Faries MB
    JAMA Surg; 2013 Sep; 148(9):879-84. PubMed ID: 23903435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Size of sentinel node metastases predicts other nodal disease and survival in malignant melanoma.
    Pearlman NW; McCarter MD; Frank M; Hurtubis C; Merkow RP; Franklin WA; Gonzalez R; Lewis K; Roaten JB; Robinson WA
    Am J Surg; 2006 Dec; 192(6):878-81. PubMed ID: 17161112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
    Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
    Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sentinel lymph node biopsy in patients with thin melanomas: Frequency and predictors of metastasis based on analysis of two large international cohorts.
    Isaksson K; Nielsen K; Mikiver R; Nieweg OE; Scolyer RA; Thompson JF; Ingvar C
    J Surg Oncol; 2018 Sep; 118(4):599-605. PubMed ID: 30196533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathologic predictors of sentinel lymph node metastasis in thin melanoma.
    Han D; Zager JS; Shyr Y; Chen H; Berry LD; Iyengar S; Djulbegovic M; Weber JL; Marzban SS; Sondak VK; Messina JL; Vetto JT; White RL; Pockaj B; Mozzillo N; Charney KJ; Avisar E; Krouse R; Kashani-Sabet M; Leong SP
    J Clin Oncol; 2013 Dec; 31(35):4387-93. PubMed ID: 24190111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should all patients with melanoma between 1 and 2 mm Breslow thickness undergo sentinel lymph node biopsy?
    Mays MP; Martin RC; Burton A; Ginter B; Edwards MJ; Reintgen DS; Ross MI; Urist MM; Stromberg AJ; McMasters KM; Scoggins CR
    Cancer; 2010 Mar; 116(6):1535-44. PubMed ID: 20108306
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Greater Tumor Thickness, Ulceration, and Positive Sentinel Lymph Node Are Associated With Worse Prognosis in Patients With Conjunctival Melanoma: Implications for Future AJCC Classifications.
    Esmaeli B; Rubin ML; Xu S; Goepfert RP; Curry JL; Prieto VG; Ning J; Tetzlaff MT
    Am J Surg Pathol; 2019 Dec; 43(12):1701-1710. PubMed ID: 31425167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 332.